A Decade of SG&A: GSK plc vs. Geron Corporation

In the ever-evolving pharmaceutical landscape, operational efficiency is paramount. Over the past decade, GSK plc and Geron Corporation have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. GSK, a global healthcare giant, consistently reported SG&A expenses averaging around $9.8 billion annually, peaking in 2020. This reflects their expansive global operations and robust marketing strategies. In contrast, Geron Corporation, a smaller biotech firm, maintained a leaner approach with expenses averaging $28 million, highlighting their focus on niche markets and innovation.

Key Insights

• GSK's Fluctuations: Notably, GSK's expenses surged by 39% from 2014 to 2020, before a slight dip in 2022.
• Geron's Growth: Geron saw a 312% increase in SG&A from 2014 to 2023, indicating strategic scaling.

These trends underscore the diverse operational strategies within the pharmaceutical sector.